Aptamer-functionalized superporous hydrogels for sequestration and release of growth factors regulated via molecular recognition

Biomaterials

Volumn 35, Issue 27, 2014, Pages 8040-8048

  Battig, Mark R ^a   Huang, Yike ^a   Chen, Niancao ^a   Wang, Yong ^a  

^a The Center for Nanotechnology Education and Utilization   (United States)

Author keywords

Affinity; Controlled drug release; Growth factors; Hydrogel; Porosity; Protein adsorption

Indexed keywords

BINDING ENERGY; DISEASE CONTROL; POLYMERS; POROSITY;

AFFINITY; CLINICAL APPLICATION; CONTROLLED DRUG RELEASE; GROWTH FACTOR; POLYMERIC DELIVERY SYSTEMS; PROTEIN ADSORPTION; REACTION CONDITIONS; SUPERPOROUS HYDROGELS;

HYDROGELS;

APTAMER; GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR BB; COMPLEMENTARY DNA; HYDROGEL; PLATELET DERIVED GROWTH FACTOR B; PLATELET-DERIVED GROWTH FACTOR BB;

ARTICLE; DNA SEQUENCE; DRUG DISTRIBUTION; DRUG RELEASE; FLOW CYTOMETRY; HYDROGEL; MOLECULAR RECOGNITION; POLYMERIZATION; PRIORITY JOURNAL; PROTEIN SECONDARY STRUCTURE; PROTEIN SECRETION; SUPERPOROUS HYDROGEL; SYNTHESIS; CHEMICAL STRUCTURE; CHEMISTRY; HUMAN; METABOLISM; MOLECULAR GENETICS; NUCLEIC ACID HYBRIDIZATION; NUCLEOTIDE SEQUENCE; POROSITY;

APTAMERS, NUCLEOTIDE; BASE SEQUENCE; DNA, COMPLEMENTARY; DRUG LIBERATION; HUMANS; HYDROGELS; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; NUCLEIC ACID HYBRIDIZATION; POROSITY; PROTO-ONCOGENE PROTEINS C-SIS;

EID: 84903463946     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2014.06.001     Document Type: Article

References (49)

1. Assenberg R., Wan P.T., Geisse S., Mayr L.M. Advances in recombinant protein expression for use in pharmaceutical research. Curr Opin Struct Biol 2013, 23:393-402.
2. Bandaranayake A.D., Almo S.C. Recent advances in mammalian protein production. FEBS Lett 2014, 588:253-260.
3. Zhu J. Mammalian cell protein expression for biopharmaceutical production. Biotechnol Adv 2012, 30:1158-1170.
4. Henry T.D., Annex B.H., McKendall G.R., Azrin M.A., Lopez J.J., Giordano F.J., et al. The VIVA Trial: vascular endothelial growth factor in ischemia for vascular angiogenesis. Circulation 2003, 107:1359-1365.
5. Kontermann R.E. Strategies for extended serum half-life of protein therapeutics. Curr Opin Biotechnol 2011, 22:868-876.
6. Baselga J., Gelmon K.A., Verma S., Wardley A., Conte P., Miles D., et al. Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy. JClin Oncol 2010, 28:1138-1144.
7. Ezan E. Pharmacokinetic studies of protein drugs: past, present and future. Adv Drug Deliv Rev 2013, 65:1065-1073.
8. Sullivan D.H., Carter W.J., Warr W.R., Williams L.H. Side effects resulting from the use of growth hormone and insulin-like growth factor-I as combined therapy to frail elderly patients. JGerontol A Biol Sci Med Sci 1998, 53A:M183-M187.
9. Hansel T.T., Kropshofer H., Singer T., Mitchell J.A., George A.J.T. The safety and side effects of monoclonal antibodies. Nat Rev Drug Discov 2010, 9:325-338.
10. Feldman D.R., Baum M.S., Ginsberg M.S., Hassoun H., Flombaum C.D., Velasco S., et al. Phase I trial of bevacizumab plus escalated doses of sunitinib in patients with metastatic renal cell carcinoma. JClin Oncol 2009, 27:1432-1439.
11. Giri J., Li W.J., Tuan R.S., Cicerone M.T. Stabilization of proteins by nanoencapsulation in sugar-glass for tissue engineering and drug delivery applications. Adv Mater 2011, 23:4861-4867.
12. Wu E.C., Zhang S., Hauser C.A.E. Self-assembling peptides as cell-interactive scaffolds. Adv Funct Mater 2012, 22:456-468.
13. Oyen M.L. Mechanical characterisation of hydrogel materials. Int Mater Rev 2014, 59:44-59.
14. Langer R., Folkman J. Polymers for sustained-release of proteins and other macromolecules. Nature 1976, 263:797-800.
15. Lin C.C., Metters A.T. Metal-chelating affinity hydrogels for sustained protein release. JBiomed Mater Res A 2007, 83A:954-964.
16. Edelman E., Mathiowitz E., Langer R., Klagsbrun M. Controlled and modulated release of basic fibroblast growth factor. Biomaterials 1991, 12:619-626.
17. Johnson N.R., Wang Y. Controlled delivery of heparin-binding EGF-like growth factor yields fast and comprehensive wound healing. JControl Release 2013, 166:124-129.
18. Lee J., Choi W.I., Tae G., Kim Y.H., Kang S.S. Enhanced regeneration of the ligament-bone interface using a poly(L-lactide-co-epsilon-caprolactone) scaffold with local delivery of cells/BMP-2 using a heparin-based hydrogel. Acta Biomater 2011, 7:244-257.
19. Taylor S.J., McDonald J.W., Sakiyama-Elbert S.E. Controlled release of neurotrophin-3 from fibrin gels for spinal cord injury. JControl Release 2004, 98:281-294.
20. Soontornworajit B., Zhou J., Shaw M.T., Fan T.H., Wang Y. Hydrogel functionalization with DNA aptamers for sustained PDGF-BB release. Chem Commun 2010, 46:1857-1859.
21. Battig M.R., Soontornworajit B., Wang Y. Programmable release of multiple protein drugs from aptamer-functionalized hydrogels via nucleic acid hybridization. JAm Chem Soc 2012, 134:12410-12413.
22. Ellington A.D., Szostak J.W. Invitro selection of RNA molecules that bind specific ligands. Nature 1990, 346:818-822.
23. Tuerk C., Gold L. Systematic evolution of ligands by exponential enrichment - RNA ligands to bacteriophage-T4 DNA-polymerase. Science 1990, 249:505-510.
24. Jayasena S.D. Aptamers: an emerging class of molecules that rival antibodies in diagnostics. Clin Chem 1999, 45:1628-1650.
25. Gemeinhart R.A., Park H., Park K. Pore structure of superporous hydrogels. Polym Adv Technol 2000, 11:617-625.
26. Chen J., Park H., Park K. Synthesis of superporous hydrogels: hydrogels with fast swelling and superabsorbent properties. JBiomed Mater Res 1999, 44:53-62.
27. Reuter J.S., Mathews D.H. RNAstructure: software for RNA secondary structure prediction and analysis. BMC Bioinformatics 2010, 11:129-137.
28. Steenberg C.D., Bois J.S., Wolfe B.R., Pierce M.B. NUPACK: analysis and design of nucleic acid systems. JComput Chem 2011, 32:170-173.
29. Mikos A.G., Sarakinos G., Leite S.M., Vacanti J.P., Langer R. Laminated three-dimensional biodegradable foams for use in tissue engineering. Biomaterials 1993, 14:323-330.
30. Ohji T., Fukushima M. Macro-porous ceramics: processing and properties. Int Mater Rev 2012, 57:115-131.
31. Schugens C., Maquet V., Grandfils C., Jerome R., Teyssie P. Biodegradable and macroporous polylactide implants for cell transplantation: 1. Preparation of macroporous polylactide supports by solid-liquid phase separation. Polymer 1996, 37:1027-1038.
32. Kettunen M., Silvennoinen R.J., Houbenov N., Nykanen A., Ruokolainen J., Sainio J., et al. Photoswitchable superabsorbency based on nanocellulose aerogels. Adv Funct Mater 2011, 21:510-517.
33. Park A., Wu B., Griffith L.G. Integration of surface modification and 3D fabrication techniques to prepare patterned poly(L-lactide) substrates allowing regionally selective cell adhesion. JBiomater Sci Polym Ed 1998, 9:89-110.
34. Green L.S., Jellinek D., Jenison R., Ostman A., Heldin C.H., Janjic N. Inhibitory DNA ligands to platelet-derived growth factor B-chain. Biochemistry 1996, 35:14413-14424.
35. Shin S.H., Lee J., Ahn D.G., Lee K.Y. Co-delivery of vascular endothelial growth factor and angiopoietin-1 using injectable microsphere/hydrogel hybrid systems for therapeutic angiogenesis. Pharm Res 2013, 30:2157-2165.
36. Jiang B., Zhang G., Brey E.M. Dual delivery of chlorhexidine and platelet-derived growth factor-BB for enhanced wound healing and infection control. Acta Biomater 2013, 9:4976-4984.
37. Xu W., Atala A., Yoo J.J., Lee S.J. Controllable dual protein delivery through electrospun fibrous scaffolds with different hydrophilicities. Biomed Mater 2013, 8:14104-14111.
38. Putney S.D., Burke P.A. Improving protein therapeutics with sustained-release formulations. Nat Biotechnol 1998, 16:153-157.
39. Bilati U., Allemann E., Doelker E. Strategic approaches for overcoming peptide and protein instability within biodegradable nano- and microparticles. Eur J Pharm Biopharm 2005, 59:375-388.
40. Abbah S.A., Liu J., Goh J.C.H., Wong H.K. Enhanced control of invivo bone formation with surface functionalized alginate microbeads incorporating heparin and human bone morphogenetic protein-2. Tissue Eng Part A 2012, 19:350-359.
41. Ishimaru T., Komura M., Komura H., Otani Y., Komuro H., Sugiyma M., et al. Slow release of basic fibroblast growth factor (b-FGF) promotes growth of tracheal cartilage. JPediatr Surg 2013, 48:288-292.
42. Cipitria A., Reichert J.C., Epari D.R., Saifzadeh S., Berner A., Schell H., et al. Polycaprolactone scaffold and reduced rhBMP-7 dose for the regeneration of critical-sized defects in sheep tibiae. Biomaterials 2013, 34:9960-9968.
43. Spiller K.L., Liu Y., Holloway J.L., Maher S.A., Cao Y., Liu W., et al. Anovel method for the direct fabrication of growth factor-loaded microspheres within porous nondegradable hydrogels: controlled release for cartilage tissue engineering. JControl Release 2012, 157:39-45.
44. Hammers D.W., Sarathy A., Pham C.B., Drinnan C.T., Farrar R.P., Suggs L.J. Controlled release of IGF-I from a biodegradable matrix improves functional recovery of skeletal muscle from ischemia/reperfusion. Biotechnol Bioeng 2012, 109:1051-1059.
45. Fujita N., Matsushita T., Ishida K., Sasaki K., Kubo S., Matsumoto T., et al. An analysis of bone regeneration at a segmental bone defect by controlled release of bone morphogenetic protein 2 from a biodegradable sponge composed of gelatin and ß-tricalcium phosphate. JTissue Eng Regen Med 2012, 6:291-298.
46. Oliviero O., Ventre M., Netti P.A. Functional porous hydrogels to study angiogenesis under the effect of controlled release of vascular endothelial growth factor. Acta Biomater 2012, 8:3294-3301.
47. Richardson T.P., Peters M.C., Ennett A.B., Mooney D.J. Polymeric system for dual growth factor delivery. Nat Biotechnol 2001, 19:1029-1034.
48. Rusconi C.P., Scardino E., Layzer J., Pitoc G.A., Ortel T.L., Monroe D., et al. RNA aptamers as reversible antagonists of coagulation factor IXa. Nature 2002, 419:90-94.
49. Bompiani K.M., Monroe D.M., Church F.C., Sullenger B.A. Ahigh affinity, antidote-controllable prothrombin and thrombin-binding RNA aptamer inhibits thrombin generation and thrombin activity. JThromb Haemost 2012, 10:870-880.